Johnson & Johnson (NYSE:JNJ) Shares Bought by apricus wealth LLC

apricus wealth LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,469 shares of the company’s stock after purchasing an additional 640 shares during the period. apricus wealth LLC’s holdings in Johnson & Johnson were worth $1,969,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Easterly Investment Partners LLC lifted its position in shares of Johnson & Johnson by 6.3% in the second quarter. Easterly Investment Partners LLC now owns 85,144 shares of the company’s stock valued at $12,445,000 after acquiring an additional 5,028 shares in the last quarter. Raymond James Trust N.A. lifted its position in shares of Johnson & Johnson by 0.4% in the second quarter. Raymond James Trust N.A. now owns 217,494 shares of the company’s stock valued at $31,789,000 after acquiring an additional 868 shares in the last quarter. Wedgewood Investors Inc. PA purchased a new position in shares of Johnson & Johnson in the second quarter valued at approximately $1,422,000. Capital Advisors Ltd. LLC lifted its position in shares of Johnson & Johnson by 5.5% in the second quarter. Capital Advisors Ltd. LLC now owns 3,538 shares of the company’s stock valued at $517,000 after acquiring an additional 185 shares in the last quarter. Finally, Northcape Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.9% in the second quarter. Northcape Wealth Management LLC now owns 24,890 shares of the company’s stock valued at $3,638,000 after acquiring an additional 693 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. The Goldman Sachs Group reduced their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Morgan Stanley lifted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. TD Cowen reduced their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Up 0.3 %

Shares of NYSE:JNJ opened at $164.65 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a market capitalization of $396.26 billion, a PE ratio of 10.26, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The firm’s 50-day moving average is $154.30 and its two-hundred day moving average is $153.26. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $166.21.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.80 earnings per share. Analysts predict that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.